Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.35 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.35 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.35 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.35 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | ABHD16A | O95870 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1255461 | 1.00 | SMN1; SMN2 (0.41) | SMN1; SMN2HPGDHTTHDAC3HDAC4 | |
| SCHEMBL2734922 | 0.99 | SMN1; SMN2 (0.39) | SMN1; SMN2HPGDHTTHDAC3HDAC4 | |
| SCHEMBL180975 | 0.97 | SMN1; SMN2 (0.45) | SMN1; SMN2HPGDHTTHDAC3HDAC4 | |
| SCHEMBL8663263 | 0.94 | SMN1; SMN2 (0.37) | SMN1; SMN2HPGDHTTLMNA | |
| SCHEMBL26382038 | 0.90 | SMN1; SMN2 (0.50) | SMN1; SMN2HPGDHTTHDAC3HDAC4 | |
| SCHEMBL17767812 | 0.90 | SMN1; SMN2 (0.50) | SMN1; SMN2HPGDHTTHDAC3HDAC4 | |
| SCHEMBL17767809 | 0.90 | SMN1; SMN2 (0.50) | SMN1; SMN2HPGDHTTHDAC3HDAC4 | |
| SCHEMBL20999873 | 0.90 | SMN1; SMN2 (0.50) | SMN1; SMN2HPGDHTTHDAC3HDAC4 | |
| SCHEMBL17168743 | 0.90 | SMN1; SMN2 (0.50) | SMN1; SMN2HPGDHTTHDAC3HDAC4 | |
| SCHEMBL31128140 | 0.89 | EPHX2 (0.45) | SMN1; SMN2KMT2AEPHX2CASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1371 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240293524-A1 | MULTIPLE FUNCTIONALIZED noMV CONJUGATES | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-09-05 | — | — | US | claimed |
| US-11712423-B2 | Methods and compositions for modifying mucous membranes | ABBOTT NICHOLAS L (US) | 2023-08-01 | — | — | US | claimed |
| CN-116068167-A | Separation and detection method of extracellular biomacromolecule | 厦门福流生物科技有限公司 | 2023-05-05 | — | — | CN | claimed |
| US-20230137914-A1 | nOMV-ANTIGEN CONJUGATED COMPOUNDS AND USE THEREOF | GLAXOSMITHKLINE BIOLOGICALS, S.A. (BE) | 2023-05-04 | — | — | US | claimed |
| US-20220008529-A1 | MULTI-FUNCTIONALIZED noMV CONJUGATES | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2022-01-13 | — | — | US | claimed |
| EP-3799883-A1 | NOMV-ANTIGEN CONJUGATED COMPOUNDS AND USE THEREOF | GlaxoSmithKline Biologicals S.A. (BE) | 2021-04-07 | — | — | EP | claimed |
| EP-3664837-A1 | MULTI-FUNCTIONALIZED nOMV CONJUGATES | GlaxoSmithKline Biologicals S.A. (BE) | 2020-06-17 | — | — | EP | claimed |
| EP-3544637-A1 | nOMV-ANTIGEN CONJUGATES AND USE THEREOF | GlaxoSmithKline Biologicals S.A. (BE) | 2019-10-02 | — | — | EP | claimed |
| WO-2019030271-A1 | MULTI-FUNCTIONALIZED nOMV CONJUGATES | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2019-02-14 | — | — | WO | claimed |
| US-20180263927-A1 | AFFINITY MEDICANT CONJUGATE | AF CHEMICALS, LLC (US) | 2018-09-20 | — | — | US | claimed |
| WO-2010111271-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | SDG, INC. (AN OHIO CORPORATION) (US) | 2010-09-30 | — | — | WO | claimed |
| CN-101790684-A | Improvements in or relating to the preparation of conjugates | INNOVA BIOSCIENCES LTD | 2010-07-28 | — | — | CN | claimed |
| US-20100184184-A1 | Production of Conjugates | INNOVA BIOSCIENCES LIMITED (GB) | 2010-07-22 | — | — | US | claimed |
| EP-2171457-A2 | IMPROVEMENTS IN OR RELATING TO PRODUCTION OF CONJUGATES | Innova Biosciences Limited (GB) | 2010-04-07 | — | — | EP | claimed |
| US-20100080773-A1 | Orally Bioavailable Lipid-Based Constructs | SDG, INC. | 2010-04-01 | — | — | US | claimed |
| WO-2008152424-A2 | IMPROVEMENTS IN OR RELATING TO PRODUCTION OF CONJUGATES | INNOVA BIOSCIENCES LIMITED (GB) | 2008-12-18 | — | — | WO | claimed |
| US-20030148304-A1 | Method for immobilisation | KAROLINSKA INNOVATIONS AB (SE) | 2003-08-07 | — | — | US | claimed |
| EP-1235937-A1 | METHOD FOR IMMOBILISATION | Karolinska Innovations AB (SE) | 2002-09-04 | — | — | EP | claimed |
| US-6335176-B1 | REAGENT IS SUCCINIMIDYL MOIETY LINKED TO KINASE SUBSTRATE; CAN BE LINKED TO FREE PRIMARY OR SECONDARY AMINE IN COMPOUND TO BE PHOSPHORYLATED | PHARMACOPEIA, INC. | 2002-01-01 | — | — | US | claimed |
| WO-2001042501-A1 | METHOD FOR IMMOBILISATION | KAROLINSKA INNOVATIONS AB (SE) | 2001-06-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100080773-A1 | Orally Bioavailable Lipid-Based Constructs | FABP2, FABP1, LIPC | SMN1; SMN2 3813/4885HPGD 1187/4885HTT 561/4885 |
| US-20230137914-A1 | nOMV-ANTIGEN CONJUGATED COMPOUNDS AND USE THEREOF | VAPB, CD14, CHMP4B | SMN1; SMN2 4307/4885HPGD 2833/4885HTT 3446/4885 |
| US-20240293524-A1 | MULTIPLE FUNCTIONALIZED noMV CONJUGATES | CD14, VAPB, CHMP4B | SMN1; SMN2 4171/4885HPGD 4105/4885HTT 3654/4885 |
| US-20220008529-A1 | MULTI-FUNCTIONALIZED noMV CONJUGATES | CD14, CHMP4B, VAPB | SMN1; SMN2 4243/4885HPGD 4079/4885HTT 3984/4885 |
| US-20180263927-A1 | AFFINITY MEDICANT CONJUGATE | FCER2, HDGF, FCGR2A | SMN1; SMN2 3267/4885HPGD 2885/4885HTT 3671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.